EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting PI3Kγ in cancer

Giuliana P Mognol, Anghesom Ghebremedhin, Judith A Varner

Trends in Cancer · 2025-05 · 11 (5) · 462-474

DOI: 10.1016/j.trecan.2025.01.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025-05. Verfasst von Giuliana P Mognol und 2 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0819, USA. Hauptthemen laut MEDLINE: Class Ib Phosphatidylinositol 3-Kinase, Neoplasms, Phosphoinositide-3 Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDCR NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phosphoinositide 3-kinases (PI3Ks) have been the focus of a significant body of cancer research since their discovery nearly 40 years ago. These lipid kinases are now known to play central roles in cancer cell proliferation, survival, migration, metabolism, and immunity and serve as the target of numerous investigational and approved therapeutics. One of these kinases, the unique class IB PI3Kγ, which is highly expressed in myeloid lineage cells and myeloid leukemias, plays prominent roles in tumor immune suppression. Inhibition of this kinase has promoted improved antitumor immune responses in recent solid tumor preclinical studies and clinical trials. New studies also identify this kinase as a driver of acute myeloid leukemia self-renewal and as a new target for the treatment of aggressive leukemias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class Ib Phosphatidylinositol 3-KinaseNeoplasmsPhosphoinositide-3 Kinase InhibitorsAntineoplastic AgentsHumansAnimalsMolecular Targeted TherapySignal TransductionClinical Trials as Topic

Stichwörter der Autor:innen

PI3KγPIK3CGacute myeloid leukemia tumor stemnessmyeloid cell traffickingphosphatidylinositol-3 kinasephosphatidylinositol-3 kinase gammaphosphoinositide-3 kinase inhibitorssolid tumor inflammation

Substanzen

Class Ib Phosphatidylinositol 3-KinasePIK3CG protein, humanPhosphoinositide-3 Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0819, USA.
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0819, USA; Department of Pathology, University of California, San Diego, La Jolla, CA 92093-0819, USA. Electronic address: jvarner@health.ucs…

Förderung

  • NCI NIH HHS
  • NIDCR NIH HHS
  • National Institutes of Health National Cancer Institute
  • National Institutes of Health
  • National Institute of Dental and Craniofacial Research
  • Cancer Research Institute

Zitieren

APA

Mognol, G. P., Ghebremedhin, A., & Varner, J. A. (2025). Targeting PI3Kγ in cancer. Trends in Cancer, 11(5), 462-474. https://doi.org/10.1016/j.trecan.2025.01.008

Vancouver

Mognol GP, Ghebremedhin A, Varner JA. Targeting PI3Kγ in cancer. Trends in Cancer. 2025;11(5):462-474. doi:10.1016/j.trecan.2025.01.008

BibTeX
@article{Mognol2025,
  author = {Mognol, Giuliana P and Ghebremedhin, Anghesom and Varner, Judith A},
  title = {Targeting PI3Kγ in cancer},
  journal = {Trends in Cancer},
  year = {2025},
  volume = {11},
  number = {5},
  pages = {462--474},
  doi = {10.1016/j.trecan.2025.01.008}
}
Kostenlos starten →